This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Duration, discontinuation and continuity of ADHD treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • medication review and consideration of discontinuation drug treatment
    • a healthcare professional with training and expertise in managing ADHD should review ADHD medication at least once a year and discuss with the person with ADHD (and their families and carers as appropriate) whether medication should be continued. The review should include a comprehensive assessment of the:
      • preference of the child, young person or adult with ADHD (and their family or carers as appropriate)
      • benefits, including how well the current treatment is working throughout the day
      • adverse effects
      • clinical need and whether medication has been optimised
      • impact on education and employment
      • effects of missed doses, planned dose reductions and periods of no treatment
      • effect of medication on existing or new mental health, physical health or neurodevelopmental conditions
      • need for support and type of support (for example, psychological, educational, social) if medication has been optimised but ADHD symptoms continue to cause a significant impairment

  • consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate
    • if the decision is made to continue medication, the reasons for this should be documented

For detailed guidance the consult the full guideline (1).


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.